First Accelerated Cross-Linking Patients Treated in US
The ACOS study is a Phase 3, multi-center, randomized, controlled evaluation to study accelerated corneal collagen cross-linking in eyes with keratoconus or corneal ectasia after refractive surgery. ACOS is sponsoring the study, which will be conducted in up to 100 clinical centers across the United States. Each of the 100 clinical sites will exclusively use Avedro's KXL™ System and proprietary riboflavin for accelerated cross-linking. Clinical sites, which have Avedro's equipment installed, are now recruiting eligible keratoconic and post-LASIK ectasia patients for treatment. Go to www.nkcf.org for a list of clinical sites.
First keratoconus patients treated at the Slade and Baker Vision Center, Houston, TX
Wayne, Pennsylvania, USA, July 25, 2012: ACOS (The American-European Congress of Ophthalmic Surgery) and Avedro, Inc. jointly announce that the first patients have been treated in ACOS's accelerated cross-linking study utilizing Avedro's KXL™ System. The keratoconus patients were treated at the Slade and Baker Vision Center in Houston, Texas by Stephen Slade, MD and Greg Parkhurst, MD.
"I am extremely honored to be able to treat the first patient in the US ACOS CXL Trial. This will be the largest trial of cross-linking to date in the United States, and will use the latest equipment," said Stephen Slade, MD, Medical Monitor for the ACOS/Avedro study and ACOS President. "The idea of stopping a blinding eye disease with this very gentle technology is most gratifying to me as a corneal surgeon. I could not be more pleased for my patients."
"We are pleased to help facilitate cross-linking as a potential treatment for patients who otherwise would have limited therapeutic options," said David Muller, PhD, CEO of Avedro. "With up to 100 US clinical sites eventually participating in the study, US patients will have access to Avedro's accelerated cross-linking treatment with which patients around the world have been successfully treated."
The KXL System for Accelerated Cross-linking has received CE Mark and is commercially available in 58 countries outside the US.
ACOS, a 501(c)(6) non-profit ophthalmic society, brings ophthalmologists and innovators of technologies together to advance vision care and improve patients' quality of life. The society was established in early 2011 and represents and educates surgeons, innovators, and industry leaders who have made a significant contribution to the field of ophthalmology. ACOS provides a platform for education and advocacy representing the mutual interests of these groups.
About Avedro, Inc.
Avedro is a privately held medical device and pharmaceutical company advancing the science and technology of corneal collagen cross-linking. The Company's advanced cross-linking technology makes the treatment of keratoconus and post-LASIK ectasia safer, faster and more comfortable, while also making possible an entirely new cross-linking procedure, Lasik Xtra™, which restores the cornea's biomechanical integrity following the creation of the LASIK flap and/or excimer laser ablation during LASIK or PRK. Outside the US, Avedro has obtained CE Mark for its KXL System for performing accelerated corneal cross-linking and its family of riboflavin products. Avedro products are not for sale in the US.
Avedro, Inc.; email@example.com; 781-768-3400